Tirzepatide Achieves Up to 22.4% Weight Loss in Japanese Adults — 100% of 10 mg Group Lost ≥5%
Tirzepatide achieved 12-22.4% weight loss in Japanese adults with obesity, with 100% of the 10 mg group achieving ≥5% reduction and significant cardiometabolic improvements over 72 weeks.
Quick Facts
What This Study Found
Japanese adults (n=102): tirzepatide 5/10/15 mg achieved -12.0/-22.4/-22.1% weight loss vs -0.3% placebo at 72 weeks. ≥5% loss: 91.7/100/96.6% vs 15.4%. Significant cardiometabolic improvements. No new safety signals.
Key Numbers
How They Did This
Prespecified subpopulation analysis of 102 Japanese adults from the SURMOUNT-1 trial (NCT04184622), tirzepatide 5/10/15 mg vs placebo for 72 weeks.
Why This Research Matters
Japan has rising obesity rates. Demonstrating tirzepatide's exceptional efficacy specifically in Japanese adults supports its clinical adoption in Asia.
The Bigger Picture
Tirzepatide's performance in Japanese adults exceeds the overall trial population, consistent with meta-analyses showing greater incretin benefit in Asian populations.
What This Study Doesn't Tell Us
Subgroup analysis of 102 from larger trial. Small sample per dose group. Post-hoc ethnic comparison limited.
Questions This Raises
- ?Why does tirzepatide appear more effective in Japanese/Asian populations?
- ?Would lower doses be sufficient for Japanese patients?
- ?How does this compare to semaglutide Japanese data?
Trust & Context
- Key Stat:
- 100% response at 10 mg Every single Japanese participant on tirzepatide 10 mg achieved at least 5% weight loss — an unprecedented 100% responder rate
- Evidence Grade:
- Prespecified subpopulation analysis from pivotal Phase 3 RCT. Small but rigorous.
- Study Age:
- Published in 2025 from SURMOUNT-1 trial.
- Original Title:
- Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.
- Published In:
- Obesity (Silver Spring, Md.), 34(3), 608-621 (2026)
- Authors:
- Ishigaki, Yasushi, Yamada, Masamichi, Shingaki, Tomotaka, Oura, Tomonori, Shimomura, Iichiro
- Database ID:
- RPEP-15355
Evidence Hierarchy
Frequently Asked Questions
Does tirzepatide work well for Japanese patients?
Exceptionally well. 100% of Japanese participants on the 10 mg dose lost at least 5% body weight, with average losses of 22.4% — among the best results seen for any obesity drug.
Why might Asian patients respond better to tirzepatide?
The reasons are being studied, but may relate to differences in body composition, GLP-1/GIP receptor biology, or metabolic processing. This is consistent with other studies showing greater GLP-1 drug cardiovascular benefits in Asian populations.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15355APA
Ishigaki, Yasushi; Yamada, Masamichi; Shingaki, Tomotaka; Oura, Tomonori; Shimomura, Iichiro. (2026). Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.. Obesity (Silver Spring, Md.), 34(3), 608-621. https://doi.org/10.1002/oby.70131
MLA
Ishigaki, Yasushi, et al. "Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.." Obesity (Silver Spring, 2026. https://doi.org/10.1002/oby.70131
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of Tirzepatide in Japanese Participants ..." RPEP-15355. Retrieved from https://rethinkpeptides.com/research/ishigaki-2026-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.